Original articleAlimentary tractUse of Intestinal Ultrasound to Monitor Crohn’s Disease Activity
Section snippets
Patients
A total of 234 patients were enrolled at 47 study sites (general practices, 39.5%; general hospitals, 39.5%; university hospitals, 19.0%) in Germany between December 2010 and September 2014. Patients were eligible if they were 18 years or older with a proven diagnosis of ileocecal and/or colonic CD and with currently at least moderate disease activity measured by the Harvey-Bradshaw index (HBI score ≥7). The patients in this noninterventional, prospective, multicenter study received standard of
Patient Population
A total of 234 patients were eligible for this study; data from 134 patients with accurate time intervals between baseline and the final visit could be analyzed (analysis population [AP] 1). AP2 constitutes the second AP, and includes 182 patients with accurate time intervals between baseline and the first follow-up visit at 3 months (for the definition of accurate time intervals, see Figure 1). The baseline characteristics of the different populations are shown in Table 1 and did not reveal
Discussion
The TRUST study indicates that US can be used to effectively monitor treatment response in patients with active CD. Significant improvement in US pathology can be observed 3 months after treatment intensification. Forty-seven centers with inflammatory bowel disease specialists from different hospitals or outpatient clinics were involved in this trial. Comparable results between different gastroenterologists working at various level of medical care indicate that bowel US is a reliable tool to
Acknowledgments
The authors thank the patients for their support and their active participation in the research of IBD. They also thank all the members of the TRUST study group and their study nurses for the invaluable contributions to the success of this study. The members of the TRUST study group are listed in the Supplementary Materials. Finally, they thank Imma Fischer, Biostatistik Tübingen, for performing the statistical analyses.
References (23)
- et al.
Crohn’s disease
Lancet
(2012) - et al.
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines
J Crohns Colitis
(2013) - et al.
The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis
J Crohn's Colitis
(2010) - et al.
A simple index of Crohn’s-disease activity
Lancet
(1980) Why does Crohn’s disease usually occur in terminal ileum
J Crohn's Colitis
(2008)- et al.
Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI
Am J Gastroenterol
(2010) - et al.
Ultrasonography of chronic inflammatory bowel diseases
Eur Radiol
(2001) - et al.
Doppler ultrasound and intravenous contrast agents in gastrointestinal tract disorders: current role and future implications
Eur J Gastroenterol Hepatol
(2005) - et al.
Cross-sectional imaging modalities in Crohn's disease
Dig Dis
(2013) - et al.
Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn’s disease. A prospective comparison with conventional ultrasound, X ray studies, and ileocolonoscopy
Gut
(2004)
Crohn's disease and color Doppler sonography: response to treatment and its relationship with long-term prognosis
J Clin Ultrasound
Cited by (163)
Crohn's disease
2024, The LancetIntestinal Ultrasound and MRI for Monitoring Therapeutic Response in Luminal Crohn's Disease: A Systematic Review
2024, Journal of the American College of RadiologyEchopattern parameter as an aid to profile Crohn's disease patients
2023, Digestive and Liver DiseaseIntestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease
2024, European Journal of Gastroenterology and Hepatology
Conflicts of interest The authors disclose the following: Torsten Kucharzik has received lecture and consulting fees from AbbVie, MSD, Ferring, Falk Foundation, Takeda, UCB, Wolff Pharma, Biogen, Hospira, Mundipharma, and Janssen. Bianca M. Wittig is an employee of AbbVie, and owns AbbVie stock or options. Ulf Helwig has received lecture and consulting fees from AbbVie, MSD, Ferring, Falk Foundation, Takeda, Mundipharma, Hospira, Vifor Pharma, and Celltrion. Norbert Börner has received lecture and consulting fees from AbbVie, MSD, Ferring, Falk Foundation, and Takeda. Alexander Rössler is an employee of AbbVie, and may own AbbVie stock or options. Stefan Rath is an employee of AbbVie, and may own AbbVie stock or options. Christian Maaser has received lecture and consulting fees from AbbVie, MSD, Ferring, Falk Foundation, Takeda, and Wolff Pharma.
Funding The design, study conduct, and funding for the study were supported by AbbVie Deutschland GmbH & Co KG. All authors participated in the development of the study design, interpretation of data, review, development, and approval of the publication.